Adecatumumab clinical trials
Also written MT-201.
How each study uses adecatumumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the adecatumumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Mirador Therapeutics, Inc. (3) · Amgen Research (Munich) GmbH (1) · Michael Gunn (1)
Often tested with
Tested in the same studies.
Folfox protocol (1) · MT-501 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test adecatumumab.
- Nov 2026A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy ParticipantsPhase 1 · Mirador Therapeutics, Inc.
- Apr 2027A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel DiseasePhase 2 · Mirador Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses adecatumumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy ParticipantsRecruitingPhase 1Mirador Therapeutics, Inc.NCT07776782Written as MT-201
- A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel DiseaseRecruitingPhase 2Mirador Therapeutics, Inc.NCT07113522Written as MT-201
- A First-in-Human Single and Multiple Ascending Dose Study of MT-201CompletedPhase 1Mirador Therapeutics, Inc.NCT07219368Written as MT-201
- Monocyte Antigen Carrier Cells for Newly Diagnosed GBMWithdrawnPhase 1Michael GunnNCT04741984Written as MT-201-GBM monocyte vaccine
- Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver MetastasesCompletedPhase 2Amgen Research (Munich) GmbHNCT00866944Written as Adecatumumab
Codes
What other systems call adecatumumab · ClinicalTrials.gg INT004459
- MeSH (NLM) C460839adecatumumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 000705ZASDADECATUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3605135adecatumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82358AdecatumumabOne source FDA
- DrugBank DB05006One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C460839 | adecatumumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 000705ZASD | ADECATUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3605135 | adecatumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82358 | Adecatumumab | One source FDA |
| DrugBank | DB05006 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.